45S5 bioglass graft decreases surgical site infection after posterior transforaminal lumbar interbody fusion reconstruction compared to alternative graft materials.

Background: 45S5 bioglass synthetic bone graft is an established bone graft material with known intrinsic antimicrobial material properties well documented in the Methods: This multi-center retrospective review included all patients undergoing open TLIF procedures from 2017-2022. The minimum follow-up period was 1-year. The final included cohort consisted of 1,376 patients (470 bioglass and 906 non-bioglass). Patient demographic, comorbidity, perioperative, and acute postoperative variables were obtained for each patient and compared between groups. The primary outcome measure was SSI at 1-year postoperatively. Multivariable regression analysis was performed to compare outcomes of interest between the groups, controlling for variables with P<0.05 on univariate analysis. Results: The use of 45S5 bioglass synthetic graft for posterior TLIF was associated with a decreased risk of SSI within one year compared to patients who received non-bioglass grafts [0.6% Conclusions: Results of this multicenter retrospective analysis support an association between 45S5 bioglass graft use and a reduced risk of SSI in the setting of posterior TLIF, consistent with the intrinsic antimicrobial properties of 45S5 demonstrated in prior